Latest prices for talazoparib tosylate in 2025

Talazoparib is a representative PARP inhibitor. Its main application is concentrated in some breast cancer patients with BRCA gene mutations, especially for the treatment of hormone receptor-positive or HER2-negative types. In recent years, with the development of precision medicine, tumor-targeted drugs have gradually become the focus of treatment. Talazoparib has gradually attracted the attention of the international academic community due to its potent DNA repair inhibitory effect, and has become one of the recommended options in clinical guidelines in the field of breast cancer. In addition to breast cancer, its research in ovarian cancer, prostate cancer, pancreatic cancer and other fields is also continuing to advance, showing wider application prospects.

Regarding price, the original drug of talazoparib has been launched in China. However, because it has not been on the market for a long time, medical insurance coverage and terminal sales price are not yet fully clear. According to some channel information, the price of 30 capsules of 1mg currently sold in Hong Kong is about 50,000 yuan per box. The price of 0.25 mg 30 capsules circulating in the European market is about more than 10,000 yuan per box. The actual amount will be affected by exchange rates and import channels, and there will be certain fluctuations. It is worth noting that some generic drugs are already on the market overseas. For example, 1mg*30 tablets produced by a Laos pharmaceutical factory may cost more than 1,000 yuan per box, which is more cost-effective than original drugs. Although the ingredients are consistent with the original drug, patients still need to pay attention to production standards, quality control and legal and compliant purchasing channels.

As generic drugs gradually become available in more countries, prices are expected to fall further in the future, which will make long-term treatment affordable for more patients. Combined with current trends, the global accessibility of talazoparib is gradually improving, and the domestic market may also see a price decline after adjustments to medical insurance policies. For patients with long-term medication needs, choosing the appropriate drug source and paying attention to officially approved channels will be the key to ensuring efficacy and safety.

Reference materials:https://www.talzenna.com/